Thomas Sandgaard, the President, CEO, and Chairman, and 10% Owner of Zynex Inc (ZYXI, Financial), sold 6,000 shares of the company on November 6, 2024. The transaction was reported in a recent SEC Filing. Following this sale, the insider now owns 14,615,662 shares of Zynex Inc.
Zynex Inc, listed under the symbol ZYXI, operates in the healthcare sector, focusing on manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring, and neurological diagnostics.
Over the past year, Thomas Sandgaard has engaged in multiple transactions involving Zynex Inc shares. The insider has sold a total of 12,000 shares and has not purchased any shares during this period. The insider transaction history for Zynex Inc shows a trend with 1 insider buy and 5 insider sells over the past year.
On the day of the latest transaction, shares of Zynex Inc were trading at $8.51. This pricing values the company with a market cap of approximately $293.297 million. The price-earnings ratio of Zynex Inc stands at 65.79, significantly above both the industry median of 19.82 and the company’s historical median.
According to the GF Value, the intrinsic value of Zynex Inc is estimated at $13.19 per share, suggesting that the stock is significantly undervalued with a price-to-GF-Value ratio of 0.65.
The GF Value is calculated based on historical trading multiples like the price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, adjusted by a GuruFocus factor which considers past returns and growth, and future business performance estimates from Morningstar analysts.
This sale by the insider might be of interest to current and potential investors, providing insight into insider confidence and valuation perspectives at Zynex Inc.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
